Bionor Pharma Strengthens International Team to Expedite Development and Commercialization of its Vaccines
Oslo 11.01.2012 - Bionor Pharma ASA today announcedhiring David Sheon, President at WHITECOAT Strategies, Washington DC, USA, on aconsultancy basis to further strengthen the management team throughinternational representation. David has over 20 years of experience consultingto biotechnology and pharmaceutical companies worldwide.
David was formerly Senior Vice President, Health and Medical, Ogilvy PR
Worldwide, where he managed drug launches for major pharmaceutical companies,
such as GSK (GlaxoSmithKline). WHITECOAT Strategies is a consultancy advising
biotech and other health organizations with strategies for advancing innovative
The primary objectives for the agreement are to strengthen the international
visibility, and expedite securing a pharmaceutical/biotech partner or other
source of funding that Bionor needs for further development of the company's
therapeutic vaccine candidates.
David Sheon`s responsibilities include management of corporate communication,
including managing the news release development and distribution process
internationally. David will be working with top medical and science journalists
worldwide to educate reporters on Bionor's vaccine candidates. He will also
help direct stakeholder relations, including educational efforts to inform
global public health governmental and foundation contacts about the vital need
for next generation treatments to address HIV/AIDS, Influenza, and Hepatitis C.
More information is available at www.WHITECOATstrategies.com
About Bionor Pharma
Bionor Pharma is a biopharmaceutical company based in Oslo, Norway. The
Company's lead investigational product, the therapeutic HIV vaccine Vacc-4x, has
completed a Phase IIb multinational, placebo controlled double-blind trial,
which found a statistically significant reduction in viral load in treated
subjects. Patients given the vaccine were 70 percent more likely to remain off
ART (conventional medicine) two years after being injected with the vaccine.
Vacc-C5 is developed to induce antibodies to HIV that can reduce immune hyper
activation associated with HIV infection. Bionor intends to bring Vacc-C5 into
the clinic in 1Q 2012. Because researchers have already found that patients with
antibodies to the C5 region on HIV have little virus in their blood and slow
disease progression, Bionor anticipates that Vacc-C5 will offer an important
weapon toward finding a functional cure for HIV.
Vacc-4x in combination with Vacc-C5 can potentially revolutionize the management
of HIV infection and could form the basis for a preventative HIV vaccine.
The Company's innovative technology platform is also well suited to the
development of vaccines for a wide range of other viral diseases, such as
Influenza, HCV (Hepatitis C) and HPV (Human Papilloma Virus). Preclinical
studies on Vacc-Flu (Universal Influenza vaccine) and Vacc-HCV (Hepatitis C
vaccine) are planned to be finalized in second half 2012, preparing for the
clinical stage of development and partnering.
Bionor's vaccines are based on the proprietary technology platform developed
following more than ten years of research on peptides. The vaccines are designed
to safely activate each person's immune system to combat viral disease.
Bionor seeks to create positive cash flow at an early stage of development by
signing partnering deals with biotech and pharmaceutical companies. This
includes short-term out-licensing of products with royalty payments or direct
funding of clinical trials, such as Bionor's agreement signed in August 2011
with one of the world's largest biotech companies. The collaboration includes a
clinical trial on patients with HIV using a combination of Vacc-4x, and the
cancer drug Revlimid®.
More information about Bionor Pharma, its research and products, is available at
Bionor Pharma ASA, Oslo: +47 23 01 09 60/ Skien: +47 35 90 85 00
Steen Krøyer, CEO
David Sheon +1 202 422-6999